Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.

Abstract: An oil-in-water emulsion cosmetic containing (A) to (E) as essential components and having a pH of 6 or less: (A) an L-ascorbyl tetra fatty acid ester derivative represented by the following general formula (I) Formula 1 wherein R represents a branched alkyl fatty acid residue having 8 to 18 carbons; (B) a polar oil which is liquid at 25° C. and having an IOB value of 0.1 to 0.5; (C) a chelating agent; (D) an antioxidant; and (E) water.

Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.

Abstract: A method of treating liver fibrosis with CCR2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (T2DM) or metabolic syndrome (MS).

Abstract: The present disclosure provides methods related to treating or preventing gastrointestinal dysfunction in a subject in need thereof, which include the use of a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor. The disclosure also provides pharmaceutical compositions comprising a DGAT1 inhibitor, or pharmaceutically acceptable salts or esters thereof, useful for the treatments described herein.

Abstract: Pyridine compounds of Formula (1) are provided: wherein R1, R2, X, Y and Het are defined. The pyridine compounds can be used to treat or prevent plant diseases.

Abstract: The cis-isomer and trans-isomers of the plant-derived compound gnetin H are shown have anticancer properties, anti-inflammatory properties, and low toxicity. Therapeutic and prophylactic compositions that contain cis-gnetin H, trans-gnetin H, and derivatives thereof, as well as methods of making and using said compositions, are provided. cis-gnetin H and/or trans-gnetin H can be used in purified form or as a plant extract.

Abstract: An absorption refrigeration system (ARS), includes a sorbent-refrigerant pair that has an ionic liquid (IL) sorbent and a refrigerant that displays a lower critical lower critical solution temperature (LCST) at a temperature of 50 to 100° C., wherein the separation of the sorbent from the refrigerant occurs upon heating the sorbent-refrigerant pair to a temperature above the LCST. This liquid-liquid phase separation requires significantly less energy to desorb the refrigerant from the sorbent than vapor-liquid phase separation in traditional ABSs.

Abstract: Combination compositions and kits comprising an analgesic and an antihistamine are provided as well as methods of use in treating sunburn.

Abstract: The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

Abstract: Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitory patients treated with acamprosate.

Abstract: The present invention pertains to the field of chemical medicine, particularly to 4-substituted coumarin derivatives and preparation methods and applications thereof. The invention provides 4-substituted coumarin derivatives with a structural formula as shown in Formula I. The invention also provides preparation methods and applications for the above 4-substituted coumarin derivatives. The compounds provided in the invention have strong anti-tumor activity with IC50 for plural tumor cell lines between 0.01-5 nM, and it also performs better to inhibit microtubule polymerization and has diversified biological activities and low toxicity, providing new options for drug-sensitive and drug-resistant tumor cells.

Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

Abstract: The invention relates to oligopyridylamide alpha-helix mimetic compounds and their use to inhibit p53 aggregation and restore its tumor suppressor function for treating diseases, e.g., cancers, associated with p53 mutations, e.g., R248W p53 mutation.

Abstract: Disclosed are methods for modulating the activity of an orthosteric or allosteric drug on a group I metabotropic glutamate receptor (mGluR) by increasing or decreasing the levels of extracellular Ca2+.

Abstract: Methods for transmammary administration of an analgesic to offspring swine are disclosed, which are useful for mitigating, inhibiting, and/or reducing pain in offspring swine prior to undergoing processing procedures that would cause or result in pain. The methods generally comprise administering, via injection, a cyclooxygenase-2 inhibitor class analgesic directly to a lactating female swine. The analgesic is passed indirectly to the offspring swine through the milk of the treated lactating female swine and has beneficial effects, including increases in weight gain, performance, and decreases in pain. A single dosage form injected into the lactating female is suitable for achieving indirect therapeutically effective levels of the cyclooxygenase-2 inhibitor class analgesic in the milk for the offspring.

Abstract: The present invention generally relates to various compounds that are useful as ?-synuclein ligands. The invention further relates to methods of using these compounds and their radiolabeled analogs for the detection of synucleinopathies, including Parkinson's disease (PD).

Abstract: A method of providing a cooling effect to a product includes the incorporation into the product of at least one compound of the formula I in which m is a number between 0 and 2, X, Y and Z are selected independently from the group consisting of H, halogen, OH, Me, Et, MeO and EtO, and R1, R2 and R3 together comprise at least 6 carbons, selected such that (a) (i) R1 is selected from the group consisting of H, Me, Et, isopropyl and C4-C5 branched alkyl; and ?(ii) R2 and R3 are independently selected from the group consisting of Me, Et, isopropyl and Ca-branched alkyl; or (b) any two or all of R1, R2 and R3 together form a monocyclic, bicyclic or tricyclic radical having up to 10 carbons. The compounds confer substantial cooling effects on compositions applied to the skin or taken orally, such as toothpastes, mouthwashes, foodstuffs, beverages, confectionery, tobacco products, skin creams and ointments.

Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Abstract: The present invention relates to a skin-protection composition that comprises stilbenoid(s) and/or stilbenoid-containing extract(s) obtained from Dendrobium plants, such as Dendrobium officinale and Dendrobium nobile for the management of melanogenesis, skin-darkening and skin-aging. More particularly, it relates to the usage of Dendrobium ingredients and stilbenoids to reduce the formation of melanin in melanocytes. It also relates to the usage of Dendrobium ingredients and stilbenoids to reduce the generation of reactive oxygen species and oxidative free radicals. This invention relates to the use Dendrobium-derived extracts or ingredients or stilbenoids in the formulation of skin-protection, skin-whitening and/or anti-skin aging products.

Abstract: A medical device system and method that includes sensing a heart sound signal from a first external sensor, determining whether a pulmonary hypertension signature is detected in response to the sensed heart sound signal, sensing a lung sound signal from a second external sensor, determining whether a heart failure signature is detected in response to the sensed lung sound signal, and determining therapy parameters in response to determining whether a pulmonary hypertension signature is detected and determining whether a heart failure signature is detected.

Abstract: A nutritional supplement composition is formulated for oral administration and enhances cognitive function. It includes huperzine A, Ginkgo biloba, and acetyl-L-carnitine. The huperzine A, acetyl-L-carnitine, and Ginkgo biloba together account for at least 80 wt % of a dosage unit of the composition. The Ginkgo biloba is about 5.0% to about 12.0%, by weight of the huperzine A, acetyl-L-carnitine and Ginkgo biloba. The Ginkgo biloba and acetyl-L-carnitine are in a ratio of y:z respectively, wherein y is between about 690 and 1,030 for Ginkgo biloba and z is between about 8,000 and 12,000 for acetyl-L-carnitine.

Abstract: The present invention relates to method(s) of treating a subject afflicted with a skin disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene or a stilbene hybrid. A method of treating or reducing the likelihood of a skin disease or condition in a patient is an additional embodiment of the present invention. Preferred pharmaceutical compositions of the invention include nanoemulsions comprising a therapeutically effective amount of a substituted cis or trans-stilbene or stilbene hybrid and at least one antibiotic.

Abstract: The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs.

Abstract: A synergistic microbicidal composition having two components. The first component is a nonionic surfactant with structure: R2O(CH2CH(CH3)O)3(CH2CH2O)5H, where R2 is a mixture of C8-C14 linear alkyl groups. The second component is 2-bromo-2-nitropropane-1,3-diol. The weight ratio of the nonionic surfactant to 2-bromo-2-nitropropane-1,3-diol is from 1:0.08 to 1:0.12 or 1:0.2 to 1:1.8286.

Abstract: The subject invention provides pridopidine L-tartrate, compositions and a process for manufacture thereof.

Abstract: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or rhodiola, and acetyl-L-carnitine, and optionally further include alpha lipoic acid, rhodiola, and biotin.

Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.

Abstract: An aqueous pharmaceutical solution composition comprising between about 20 mg/ml to about 100 mg/ml of a radioprotective ?,?-unsaturated aryl sulfone, a cosolvent comprising polyethylene glycol (PEG), polypropylene glycol, polyglycerol, DMA, propylene glycol, glycerol, ethanol, sorbitol, isopropyl alcohol, or a combination thereof in an amount between about 25% and about 90% w/v, and a water soluble Vitamin E derivative, wherein the composition has a pH within the range of about 7.0 to about 9.5.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.

Abstract: Lysophosphatidic acid acyltransferase-beta (LPAAT-?) catalyzes the production of phosphatidic acid (PA) from lysophosphatidic acid (LPA). The lipid cofactor PA contributes to the activation of c-Raf, BRAF, mTOR and PKC-?. LPAAT-? expression is a prognostic factor in gynecologic malignancies and is being investigated as a therapeutic target in a variety of tumor types. A class of thiosemicarbazones was identified as inhibitors of LPAAT-? from a screen of a library of small molecules. A focused library of thiosemicarbazones derivatives was prepared and led to the development of compounds which potently inhibit LPAAT-? and inhibit the growth of MiaPaCa2 human pancreatic cancer cells.

Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.

Abstract: Provided are acetaic abiraterone trifluoroacetate, a preparation method and an application of same. The acetaic abiraterone trifluoroacetate is obtained through a salt-forming reaction between acetaic Abiraterone and trifluoroacetic acid. The acetaic abiraterone trifluoroacetate undergoes self-purification through recrystallization, and dissociation and recrystallization are performed on the purified abiraterone acetate trifluoroacetate, so that the obtained acetaic abiraterone has a high purity, a high yield and stable quality, and is capable of meeting the requirement for mass production of acetaic abiraterone.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment and a speech impairment secondary to a non degenerative disease or disorder acquired in utero, at birth or in infancy, but later manifested.

Abstract: The invention encompasses compositions and methods for use in preventing pregnancy.

Abstract: The invention is directed to formulations of bioactive compounds of limited water solubility, inhibitors of focal adhesion kinase (FAK) of the 2,4-diaminopyridine class, adapted for oral administration to patients. The formulations are self-emulsifying in the gastrointestinal tract of the patients, providing enhanced absorption and bioavailability of the bioactive compounds as dispersions or emulsions in an oil base. For example, esters of PEG-ylated glycerol can be used as the oil, in conjunction with surfactants such as lecithin and TEPG succinate and solubilizers such as PEG 400 to provide useful oral formulations for administration to patients having a malcondition wherein inhibition of FAK is medically indicated, such as cancer or arthritis.

Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder.

Abstract: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or rhodiola, and acetyl-L-carnitine, and optionally further include alpha lipoic acid, rhodiola, and biotin.

Abstract: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder.

Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.

Abstract: The invention discloses a method for the treatment of diseases, particularly those diseases characterized by diminished or aberrant cellular function, including AIDS, cancer, and Alzheimer's Disease. The method comprises administering a therapeutically effective amount of rosuvastatin enantiomer compounds in their (3R, 5R), (3S, 5R), or (3S, 5S) configurations, or pharmaceutically acceptable salts thereof. Biologically-active rosuvastatin enantiomer compounds with (3R, 5R), (3S, 5R), and (3S, 5S) stereochemistry are also disclosed.

Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.

Abstract: The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors.

Abstract: The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors.

Abstract: A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child.

Abstract: Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR? and PPAR? activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Abstract: The present invention generally relates to compounds that inhibit haematopoietic-prostaglandin D2 synthase (H-PGDS), to compositions containing them and to their use in treating or preventing conditions and diseases associated with H-PGDS, such as allergies and inflammation.